← The Wire
ESPRNasdaq
Esperion Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1434868
Esperion develops and commercializes non-statin medicines for patients at risk for cardiovascular disease and elevated LDL-C
red 8-K · 90d
$812M
Market cap
$3.15
Last close
-0.6%
1D
-0.3%
5D
5.7M
Volume
Price · last 39 sessions+1.0%
May 4L $3.12 · H $3.17Jun 29
307
Total filings
Jun 18, 2026
Last filing
12/31
Fiscal year end
8-K/ACompany UpdateJun 18, 2026DEFA14ADEFA14AJun 16, 20268-KCompany UpdateJun 16, 20268-KCompany UpdateJun 9, 20268-KExecutive Change · Shareholder VoteJun 1, 202610-Q10-QMay 8, 2026DEFA14ADEFA14AMay 4, 2026DEFA14ADEFA14AMay 1, 2026DEFA14ADEFA14AMay 1, 20268-KMaterial Agreement · Reg FD DisclosureMay 1, 2026DEFA14ADEFA14AApr 16, 2026DEF 14ADEF 14AApr 16, 20268-KMaterial Agreement · Acquisition / DispositionApr 2, 202610-K10-KMar 10, 20268-KResults of OperationsMar 10, 20268-KMaterial Agreement · Reg FD DisclosureMar 3, 20268-KResults of OperationsJan 12, 202610-Q10-QNov 6, 20258-KResults of OperationsNov 6, 20258-KExecutive Change · Reg FD DisclosureNov 4, 20258-KMaterial Agreement · Company UpdateOct 8, 2025424B5424B5Oct 8, 2025424B5424B5Oct 7, 20258-KCompany UpdateOct 7, 202510-Q10-QAug 13, 20258-K/AResults of OperationsAug 11, 20258-KResults of OperationsAug 5, 20258-KExecutive Change · Reg FD DisclosureJul 1, 20258-KExecutive Change · Shareholder VoteJun 2, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 6, 2025424B5424B5Apr 30, 2025DEFA14ADEFA14AApr 17, 2025DEF 14ADEF 14AApr 17, 20258-KExecutive ChangeApr 4, 20258-KExecutive ChangeApr 1, 202510-K10-KMar 7, 20258-KResults of OperationsMar 4, 20258-KResults of OperationsJan 16, 20258-KMaterial Agreement · New Debt / ObligationDec 18, 20248-KMaterial Agreement · New Debt / ObligationDec 13, 2024SC 13GSC 13GNov 8, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 7, 2024SC 13GSC 13GOct 22, 202410-Q10-QAug 12, 20248-KResults of OperationsAug 12, 20248-KExecutive ChangeAug 5, 20248-KMaterial Agreement · Agreement TerminatedJun 28, 2024SC 13GSC 13GJun 12, 20248-KExecutive Change · Shareholder VoteMay 28, 20248-KCompany UpdateMay 8, 202410-Q10-QMay 7, 20248-KResults of OperationsMay 7, 2024DEF 14ADEF 14AApr 11, 202410-K10-KFeb 27, 20248-KResults of OperationsFeb 27, 20248-KMaterial Agreement · Company UpdateJan 22, 2024424B5424B5Jan 22, 20248-KReg FD DisclosureJan 18, 2024424B5424B5Jan 18, 20248-KResults of OperationsJan 11, 20248-KMaterial Agreement · Reg FD DisclosureJan 3, 202410-Q10-QNov 7, 20238-KResults of OperationsNov 7, 2023SC 13GSC 13GOct 5, 2023SC 13GSC 13GAug 29, 2023SC 13GSC 13GAug 28, 202310-Q10-QAug 1, 20238-KResults of OperationsAug 1, 20238-KReg FD Disclosure · Company UpdateJun 26, 20238-KExecutive Change · Bylaw AmendmentJun 15, 2023DEFA14ADEFA14AMay 25, 202310-Q10-QMay 9, 20238-KResults of OperationsMay 9, 20238-KCompany UpdateMay 4, 2023DEF 14ADEF 14AApr 13, 2023SC 13GESPERION THERAPEUTICS, INC.Apr 5, 20238-KCompany UpdateMar 27, 20238-KMaterial Agreement · Company UpdateMar 22, 2023
Insider Activity
In the 90 days to Mar 17, 2026: 3 sold $335K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 17, 2026 | Koenig Sheldon L.President and CEO | Sell | 25,578 | $2.72 | $70K |
| Mar 17, 2026 | Halladay BenjaminChief Financial Officer | Sell | 6,424 | $2.71 | $17K |
| Mar 17, 2026 | Looker BenjaminChief Legal Officer | Sell | 5,708 | $2.70 | $15K |
| Jan 20, 2026 | Looker BenjaminGeneral Counsel | Sell | 1,689 | $2.88 | $5K |
| Dec 17, 2025 | Koenig Sheldon L.President and CEO | Sell | 48,244 | $3.67 | $177K |
| Dec 17, 2025 | Halladay BenjaminChief Financial Officer | Sell | 7,337 | $3.67 | $27K |
| Dec 17, 2025 | Looker BenjaminGeneral Counsel | Sell | 6,517 | $3.67 | $24K |
| Oct 17, 2025 | Looker BenjaminGeneral Counsel | Sell | 1,248 | $2.62 | $3K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance